Isis Pharma, Janssen Biotech partner

January 5, 2015 12:36 PM

4 0

Isis Pharmaceuticals will get $35 million upfront and potentially nearly $800 million more and royalties in a collaboration with Janssen Biotech to develop Isis' first orally active drugs.

Carlsbad's Isis will develop drugs to treat autoimmune diseases of the gut under the deal, announced Monday. The company is eligible to get nearly $800 million more in milestone payments and license fees. It will also get royalties averaging in the double digits for any products that reach the marke...

Also read: Lockheed Martin receives two F-22 Raptor contract modifications

Read more

To category page